Table 1.
Adverse events across studies (%)
| Placebo31,32,33,34,35 | 50 mg34,35 | 100 mg32,34,35 | 200 mg31,32,33 | 400 mg31,32 | |
|---|---|---|---|---|---|
| Nausea | 8–11 | 17–27 | 16–35 | 30–46 | 41–50 |
| Dizziness | 2–12 | 10–17 | 7–17 | 15–16 | 14–19 |
| Dry mouth | 4–12 | 10 | 16–17 | 19–26 | 23–25 |
| Constipation | 3–6 | 8–9 | 5–12 | 9–17 | 14 |
| Insomnia | 8–11 | 8–9 | 9–22 | 17–18 | 30 |
| Asthenia | 3–7 | 6–7 | 7 | 11 | 10–16 |
| Anorexia | 2–3 | 5 | 4–12 | 12–13 | 10–14 |
| Somnolence | 2–8 | 5 | 13–20 | 10–22 | 6–26 |
| Sweating | 3–7 | 5–6 | 10 | 16–28 | 21–29 |
| Sexual dysfunction | 0–5 | – | 1.4–3 | 2–8 | 2–15 |
| Anxiety | 1–4 | 3 | 5 | 5 | 6 |
| Abnormal Vision (including blurred vision) | 0–1 | 5 | 3 | 6 | 2 |
| Tremor | 0–1 | – | 4 | 8–9 | 8–10 |
| Tachycardia | 2 | – | 3 | 3 | 5 |
| Taste perversion | 2 | – | <1 | <1 | 5 |
| Vasodilatation | 0 | – | 2 | 5 | 4 |
| Yawn | 0 | – | 3–7 | 5–7 | 2 |